Storia in 7 fonti

FDA OKs Takeda, Protagonist drug for rare blood cancer

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo11 g fa

FDA OKs Takeda, Protagonist drug for rare blood cancer

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.

originale

Timeline cronologica

venerdì 28 agosto 2026·endpoints.news
FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder
FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.
venerdì 28 agosto 2026·morningstar.com
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

FDA OKs Takeda, Protagonist drug for rare blood cancer

Confronto fonti

FDA OKs Takeda, Protagonist drug for rare blood cancer

Timeline cronologica

FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

FDA approves Protagonist and Takeda’s drug for rare blood cancer

FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment…

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

FDA approves Protagonist and Takeda’s drug for rare blood cancer

FDA OKs Takeda, Protagonist drug for rare blood cancer

Mimrylo snags FDA approval for first-of-its-kind polycythemia vera treatment

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)